In Vivo recently published a profile on how Italian biotech AAVantgarde is advancing dual-vector AAV gene therapy for two inherited retinal diseases (Stargardt and Usher syndrome type 1B) using a staged de-risking strategy that leverages data from one programme to underpin the next.

Read the full story here.